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ABSTRACT
Objectives: Downregulation of DIRAS3 (DIRAS family, GTP-binding Ras-like 3) is related to ovarian and breast cancer pro-
gression. A possible mechanism that silences this gene is the promoter region DNA methylation. The potential reversibility 
of this epigenetic mechanism makes it more attractive candidate for new mode of cancer treatment. DIRAS3 regulates 
cell cycle, tumor dormancy and inhibits cancer cell growth and motility, all of which may indirectly depend on interac-
tion with STAT3 (Signal Transducer and Activator of Transcription 3) classified as a potential oncogene. The restoration of 
DIRAS3 expression could inhibit cell proliferation and invasiveness.
Material and methods: Human ovarian carcinoma cell line (A2780) and human breast cancer cell line (MCF7) were ex-
posed to two DNA methyltransferase inhibitors (DNMTi): decitabine (5-aza-2’-deoxycytidine) [25 μM and 12.5 μM] and 
RG108 [150 μM and 100 μM]. In vitro migration changes of cancer cells were examined with wound healing assay. After 
7 days of DNMTi treatment cells were harvested and DNA and RNA was isolated. The methylation status of the promoter 
sequences of DIRAS3 and STAT3 genes was determined using methylation specific PCR (MS-PCR). Level of target genes’ 
expression was quantified using quantitative reverse transcription PCR (QRT-PCR).
Results and conclusions: The in vitro wound healing assay showed changes in the migration rate of both adherent cell 
lines after DNMTi treatment compared to the untreated cells. Relative balance between methylated and unmethylated vari-
ants of DIRAS3 after MS-PCR was shifted towards unmethylated version after DNMTi treatment in A2780 cells. Statistically 
significant dose dependent effect of decitabine and RG108 on DIRAS3 expression in A2780 cells was observed. 
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INTRODUCTION
Epigenetic changes in ovarian and breast cancer 
Cancer initiation and progression is caused by various 
genetic abnormalities, such as somatic mutations or genom-
ic instability, which leads to activation of oncogenes and 
inactivation of tumor suppressor genes. Furthermore, DNA 
methylation and post-translational histone modifications 
being well-known epigenetic changes also play an impor-
tant role in tumorigenesis [1]. DNA methylation is catalyzed 
by methyltransferases (DNMT1, DNMT3A, DNMT3B, and 
DNMT3L) which are responsible for the addition of a methyl 
group to the carbon-5 position of the cytosine pyrimidine 
ring in the 5’-CpG-3’ dinucleotide. DNMT1 is involved in the 
maintenance of methylation ensuring merely the methyla-
tion pattern fidelity of replicated daughter strands, whereas 
DNMT3 is a de novo methyltransferase [2].
The two commonly described methylation patterns in 
ovarian or breast cancer are hypermethylation of promot-
ers, which most likely leads to silencing of gene and thus 
facilitating cancer formation, and hypomethylation of highly 
repeated DNA sequences, which potentially leads to aber-
rant expression of oncogenic genes [3, 4]. The presence of 
hypermethylated promoter affects genes involved in cell 
cycle, cell adhesion, apoptosis or DNA repair. It may cause 
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the inactivation of certain tumor suppressor genes, which 
is observed in different cancer types [5].
DIRAS3 and STAT3 — possible mechanisms  
of regulation of gene expression
DIRAS3 (DIRAS family, GTP-binding Ras-like 3) also 
known as ARHI (aplysia ras homolog I) or NOEY2 is a pro-
tein coding gene located on chromosome 1p31.3. The gene 
contains two exons interrupted by a large intron. About 
1 kb upstream of the transcription initiation site the first 
CpG island is found. The second island is found near the 
transcription region and the third CpG island is found in the 
exon 2 where a protein-coding region is located [6]. DIRAS3 is 
a maternally imprinted tumor suppressor gene susceptible 
to loss of paternal allele expression in the process of LOH 
(loss of heterozygosity) or by epigenetic modifications like, 
transcriptional regulation or changes in methylation pat-
tern. When expressed, this gene encodes a 26-kDa GTPase 
that belongs to the RAS superfamily of small G proteins 
with high homology to RAS and RAP but with a distinctive 
34 amino acid N-terminal extension [7]. It is expressed inter 
alia in the ovary and breast epithelial cells. A loss or down-
regulation of its expression is associated with the majority 
of ovarian and breast cancers [8–10]. DIRAS3 regulates cell 
cycle, autophagy, motility, tumor dormancy and inhibits 
cancer cell growth, which may indirectly depend on its 
interaction with STAT3 (Signal Transducer and Activator 
of Transcription 3) that has been classified as a potential 
oncogene. A phosphorylated and activated STAT3 trans-
locates to the nucleus where it increases transcription of 
other oncogenes in the tumor cells. On the other hand, 
unphosphorylated STAT3 may also activate gene expression 
by an IL-6-dependent activation [11]. Overexpression of 
this gene has been observed in breast and ovarian cancer 
[11–13]. STAT3 translocation to nucleus can be inhibited 
by DIRAS3 via direct interaction or by down regulation of 
β-integrin expression. However, it has been shown that 
acetylated STAT3 is involved in regulating the methylation 
pattern of some tumor suppressor genes e.g., it stimulates 
the methylation of the DIRAS3 promoter region, which re-
sults in down regulation of transcription [12].
DNMTi — mechanism of action of nucleoside 
and non-nucleoside analogues
There are different well-characterized strategies leading 
to inhibition of DNA methylation including DNMTs anti-
sense oligonucleosides or DNA methyltransferase inhibitors 
(DNMTi) being either nucleoside analogues or non-nucleo-
side compounds [1]. Nucleoside analogues like azacitidine 
(5-azacitidine), decitabine (5-aza-2’-deoxycytidine), zebu-
larine (1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)
oxolan-2-yl]pyrimidin-2-one), DHAC (5,6-dihydro-5-aza-
cytidine) and FCDR (5-fluoro-2’-deoxycytidine) are 
called first generation compounds. Some of them have 
already been approved (azacitidine [Vidaza®, Celgene] 
in 2004 and decitabine [Dacogen®, Janssen-Cilag] in 
2006) by the FDA (Food and Drug Administration) [14] 
for treating blood-related diseases like myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML). Yet, 
their activity against solid tumors is still under investiga-
tion (phase II of clinical research) [15]. Nucleoside-like in-
hibitors (the analogues) are first transported into cells by 
human concentrative nucleoside transporter (hCNT1) and 
then converted into active triphosphate forms that are 
integrated into the genome during S phase of cell cycle. 
Azacitidine, since it is a ribose analogue, is incorporated 
into RNA and after deoxy-conversion into DNA. Decitabine 
as a deoxyribose analogue is incorporated only into DNA 
by DNA polymerase and for this reason it is more active 
than azacitidine [15, 16]. The incorporated inhibitors 
trap the arriving enzyme by irreversible covalent bind-
ing with the catalytic cysteine of DNMTs, which prevents 
DNA synthesis and subsequently leads to toxicity, even if 
such trapped enzyme promotes its proteosomal degrada-
tion [17, 18].
In turn, non-nucleoside DNMT inhibitors directly block 
the enzyme’s catalytic site rendering it non-functional so its 
associated toxicity is lower. A three-dimensional model of 
DNMT1 catalytic domain aids at the search for such direct 
inhibitors (like tryptophan derivatives — RG108). Some of 
such inhibitors are used in the treatment of disorders where 
their DNMTs inhibitory activity comes as a secondary thera-
peutic effect (for instance procainamide derivatives reduce 
the affinity of DNMT1 to DNA).
OBJECTIVES
The analysis of the aberrant DNA methylation patterns 
and the hypermethylated promoters can provide informa-
tion about silenced tumor suppressor genes so to iden-
tify useful biomarkers of cancer progression. Moreover, 
for a reversible mechanism such as the hypermethylation 
of DNA promoters, the use of DNMT inhibitors represents 
a promising approach to cancer therapy. The main aim of 
this study is to investigate the potential influence of DNMTi 
on the expression of DIRAS3 and STAT3 genes in reference to 
changes in their promoters’ methylation level and in refer-
ence to changes in migration of cancer cells.
MATERIAL AND METHODS
Cell culture
Human ovarian carcinoma cell line (A2780, Euro-
pean Collection of Cell Culture, ECACC® 93112519) used in 
the study was established from tumor tissue of untreated 
patient. Human breast cancer cell line (MCF7, American Type 
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Culture Collection, ATCC® HTB-22™) used in the study was 
derived from pleural effusion as a metastatic site.
Cells were cultured in RPMI-1640 medium (Biowest) 
including L-glutamine, supplemented with 10% (v/v) fetal 
calf serum (Biological Industries) and 0.1% (v/v) gentamicin 
(50 mg/mL gentamicin sulfate, Biological Industries) in a hu-
midified atmosphere containing 5% CO2 at 37°C. 
Treatment with DNMTi 
Decitabine (5-aza-2’-deoxycytidine, Sigma-Aldrich) and 
RG108 (N-Phthalyl-L-tryptophan, Sigma-Aldrich) 10  mM 
stock solutions were prepared in a DMSO (dimethyl sulfox-
ide) and stored at –20°C. Cells were exposed to different con-
centrations of DNMTi (5-aza-2’-deoxycytidine of 25 μM and 
12.5 μM, RG108 of 150 μM and 100 μM) that were selected 
after a prior cytotoxicity test evaluation (data not shown). 
The medium supplemented with inhibitors was changed 
every day until cell harvesting 7 days later. Untreated control 
cells were cultured in a cell growth medium concurrently.
Wound healing assay
Migration and motility changes of cancer cells were 
examined with a wound healing assay. Similarly, cells treated 
with DNA methyltransferase inhibitors and control cells were 
seeded to achieve approximately 60–80% confluence. Using 
a sterile pipette tip (volume 20-200 μL) a straight scratch in 
the cell’s monolayer was made to simulate a wound. After 
scratching the medium was changed for a fresh growth 
medium supplemented with decitabine and RG108. The 
monolayers were then incubated at 37°C for 7 days. The in 
vitro healing and the speed of cells’ movement across the 
gap were observed. Digital documentation was made after 
scratching (at time zero) and after 7 days by an inverted 
microscope (Axiovert, Zeiss). The impact of applied modula-
tors on the migration of cells was estimated with a relative 
distance of wound closure.
RNA isolation and QRT-PCR
Total RNA was prepared using the ZR-Duet™ DNA/RNA 
MiniPrep (Zymo Research) according to the manufacturer’s 
protocol. Total RNA was converted to cDNA and relative 
quantitation of gene expression was performed with Bril-
liant II SYBR® Green QRT-PCR Master Mix Kit, 1-Step (Agi-
lent Technologies). A quantitative reverse transcription 
PCR (QRT-PCR) was performed on STRATAGENE Mx3000P 
to investigate the expression of DIRAS3, STAT3 and TBP (the 
housekeeping gene encoding TATA-box binding protein). 
A similar thermal profile was used for all the reactions: initial 
cDNA synthesis step of 30 [min] at 50°C, then 15 [min] at 
95°C followed by 40 cycles of 15 [s] at 94°C, 60 [s] at 65°C 
(for DIRAS3) or 60 [s] at 60°C (for STAT3 and TBP), and 30 [s] 
at 72°C, followed by 10 min at 72°C. 
All the primers (sequences presented in Table 1) were 
synthesized by DNA Sequencing and Oligonucleotide Syn-
thesis Laboratory of the Institute of Biochemistry and Bio-
physics at Polish Academy of Sciences in Warsaw.
The level of target genes expression was quantified us-
ing relative quantification. The ΔCq value for each sample 
was determined by calculating the difference between the 
Cq (quantitation cycle) value of the target genes (DIRAS3 and 
STAT3) and the Cq value of the endogenous reference gene 
(TBP). This was determined for every sample of cells treated 
with decitabine and RG108 and for the control untreated 
cells as calibrator sample. Next, the ΔΔCq value for each 
sample was determined by subtracting the ΔCq value of 
the calibrator from the ΔCq value of particular samples. Fi-
nally, the normalized level of target gene expression was 
calculated by using the formula: 2–ΔΔCq [19].
DNA isolation and MS-PCR
Total DNA was prepared using the ZR-Duet™ DNA/RNA 
MiniPrep (Zymo Research) according to the manufacturer’s 
protocol. The methylation status of the promoter sequences 
of DIRAS3, STAT3 and TBP genes was determined using meth-
ylation specific PCR (MS-PCR). For every subsequent MS-PCR 
a bisulfite modification of the DNA sample was carried out. 
After bisulfite treatment with Methylation-Gold™ Kit (Zymo 
Research), unmethylated cytosines were converted to ura-
cils, while 5-methylcytosines remained unaltered. Next, bi-
sulfite modified DNA was amplified by using two different 
sets of primer pairs, of which one pair (M) recognized the 
methylated alleles while the another pair (uM) recognized 
the unmethylated alleles of the promoter region of genes. All 
the primers (sequences presented in Table 2) were designed 
with MethPrimer (http://www.urogene.org/methprimer/in-
dex.html) and synthesized by DNA Sequencing and Oligonu-
cleotide Synthesis Laboratory of the Institute of Biochemis-
try and Biophysics at Polish Academy of Sciences in Warsaw.
Table 1. Primers sequences with the amplification products length
Gene Forward primer Reverse primer Product
DIRAS3 5’TGCCTCCGAGAAAGGGGTCT3’ 5’CCAAAGCTGGCGTTACCCAT3’ 99 bp
STAT3 5’GAAAACATGGCTGGCAAGGG3’ 5’GCCCATGATGTACCCTTCGT3’ 108 bp
TBP 5’TATAATCCCAAGCGGTTTGCTG3’ 5’GCCAGTCTGGACTGTTCTTCA3’ 125 bp
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For all MS-PCR reactions a similar thermal profile was 
used: initial denaturation step of 10 [min] at 95oC followed 
by 40 cycles of 30 [s] at 95oC, 30 [s] at 57oC (for DIRAS3 am-
plification) or 30 [s] at 59oC (for STAT3 and TBP amplification), 
and 40 [s] at 72oC, followed with a final extension at 72oC 
for 7 [min]. 
The MS-PCR products were separated on 2% agarose 
gels (Agarde Ultra, Roth) and stained with ethidium bromide 
(final concentration: 0.5 µg/mL) with DNA pUC Mix Marker 
8 (concentration: 0.1 μg/μL, Thermofisher). Electrophero-
grams were visualized under UV illumination using GENIUS 
IN Syngene Bio Imaging (Syngene) gel documentation sys-
tem. Next, images were analyzed using ImageJ software.
Statistical analysis
All results were analyzed statistically using the STATIS-
TICA 12.5 software. The Shapiro-Wilk test was used to deter-
mine normality. The level of significance was set at p < 0.05. 
Genes expression levels were compared using Student’s 
t test while statistical comparison of migration rate change 
was performed using (ANOVA). Tukey’s test was used for the 
analysis of significance between different values. 
RESULTS
The effect of DNA methylation inhibitors  
on gene expression and DNA methylation
Gene expression changes in A2780 and MCF-7  
in response to treatment with decitabine  
and RG108
DIRAS3 expression is reduced in ovarian and breast cancer 
cell lines, which has already been described in the literature. 
Several mechanisms may be responsible for such reduction of 
expression including primarily promoter hypermethylation. 
Consequently, this can be addressed with DNMT inhibitors as 
treatment of ovarian and breast carcinoma, which is a promis-
ing idea since epigenetic changes are reversible. 
We observed some statistically significant dose depen-
dent effects of decitabine and RG108 on DIRAS3 expression 
in A2780 cells. Compared to control cells decitabine has 
augmented the expression level of DIRAS3 mRNA 3.16-fold 
and 3.53-fold (p < 0.05) at the dose of 12.5 μM and 25 μM 
respectively. In turn, RG108 has augmented the expres-
sion of DIRAS3 mRNA 5.06-fold and 3.32-fold (p < 0.05) 
Table 2. Primers sequences with the amplification products length (M — methylated, uM — unmethylated)
Gene Forward primer Reverse primer Product
DIRAS3 M 5’TATAGGTAAGGGAGAAAGAAGTTAGAC3’ 5’GACTAAAAAACCCGATTATATCGTT3’ 130 bp
DIRAS3 uM 5’TAGGTAAGGGAGAAAGAAGTTAGATG3’ 5’AACTAAAAAACCCAATTATATCATT3’ 128 bp
STAT3 M 5’GGTTTCGGTTGTATCGTATACGT3’ 5’CCGATTAAAACTTATTCCCTCG3’ 218 bp
STAT3 uM 5’GGGGTTTTGGTTGTATTGTATATGT3’ 5’AAATCCAATTAAAACTTATTCCCTCA3’ 224 bp
TBP M 5’TTCGGTTTTAGTGGGAGTAATTC3’ 5’GAAAACGAAATTAAACAACCGAC3’ 143 bp
TBP uM 5’TTTTGGTTTTAGTGGGAGTAATTTG3’ 5’CAACAAAAACAAAATTAAACAACCA3’ 148 bp
Figure 1. Comparison of normalized DIRAS3 and STAT3 expression level (calculated with the 2–ΔΔCq formula) in A2780 cells treated with decitabine 
[25 and 12.5 μM] and RG108 [150 and 100 μM] in reference to control cells; *statistically significant results (p < 0.05)
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at respective dose of 150 μM and 100 μM (Fig. 1). On the 
other hand, decitabine and RG108 treatment of MCF7 cells 
showed no influence on the activation of DIRAS3 expres-
sion (Fig. 2).
Similarly, we have also observed statistically significant 
(p < 0.05) dose dependent effects of decitabine on STAT3 ex-
pression. Decitabine at the dose of 25 μM has decreased 
the expression of STAT3 in A2780 cells compared to control 
cells (Fig. 1).
Relative quantitation of STAT3 expression showed 
no changes after exposure to 12.5 μM decitabine and 
RG108 treatment compared to A2780 control cells.
Decitabine and RG108 treatment of MCF7 cells showed 
no influence on the activation of STAT3 expression.
The DNA methylation status of promoters  
of targeted genes in A2780 and MCF-7 cells  
in response to treatment with decitabine  
and RG108 
Electrophoretic analysis of the MS-PCR results showed 
partial methylation of DIRAS3 gene promoter fragment in the 
A2780 control cells. Relative balance between methylated 
and unmethylated variants was shifted towards unmeth-
ylated genes after treatment with DNA methyltransferase 
inhibitors. Relative density of bands determined by ImageJ 
software showed a 37.5% and 41.6% decrease of methylation 
variants after decytabine and RG108 treatment respectively 
and a 136.5% and 59.3% increase of unmethylated variants 
after decytabine and RG108 treatment respectively, all com-
pared to control cells. Electrophoretic analysis of the MS-PCR 
results of the STAT3 and TBP promoter fragments showed the 
dominance of unmethylated variant in control cells as well 
as in the cells treated with decitabine and RG108. Similar 
electrophoretic results of MS-PCR of DIRAS3, STAT3 and TBP 
fragments of genes’ promoters were observed in MCF7 cells. 
Relative density of bands determined by ImageJ soft-
ware showed a 13.9% and 9.7% decrease of methylation 
variants after decytabine and RG108 treatment respectively 
compared to control cells. All results are presented in Fig-
ure 3. The influence of reducing the methylation level within 
the promoter sequence on the increasing DIRAS3 expression 
was confirmed in A2780 cells.
Effect of DNA methylation inhibitors  
on the cells migration
To evaluate the possible influence of DNMT inhibitors 
on the increase of DIRAS3 expression we have examined 
the cellular migration of A2780 and MCF7 cells using an in 
vitro wound healing assay. The observed changes in the 
migration rate of both adherent cell lines were compared 
to the control group of untreated cells. Representative im-
ages of in vitro wound healing assay are shown in the Fig-
ure 4. We noticed a significant delay in wound closure in 
both experimental groups of cells treated with decitabine 
or RG108 compared to the control group. The rate of wound 
healing was defined as the average distance between the 
wound edges. 
Decitabine treated A2780 cells have covered the wound 
in 12.85% [25 μM] and 14.87% [12.5 μM], whereas A2780 cells 
treated with RG108 covered the wound in 5.77% [150 μM] 
and 15.48% [100 μM]. After 7 days, A2780 control cells 
covered the wound in 88.11% (Fig. 5). MCF7 cells treated 
with decitabine covered the wound in 44.97% [25 μM] and 
36.62% [12.5 μM], whereas cells treated with RG108 covered 
the wound in 34.97% [150 μM] and 47.85% [100 μM]. After 
7 days, MCF7 control cells covered the wound in 85.53% 
(Fig. 6). To sum up, both DNMT inhibitors have significantly 
(P < 0.001) reduced the speed of in vitro A2780 cells migra-
tion in comparison to untreated control cells cultured in cell 
growth medium after 7 days. Changes in speed migration of 
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Figure 2. Comparison of normalized DIRAS3 and STAT3 expression level (calculated with the 2–ΔΔCq formula) in MCF7 cells treated with decitabine 
[25 and 12.5 μM] and RG108 [150 and 100 μM] in reference to control cells
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Figure 3. Methylation status of the fragment of promoter region of DIRAS3, STAT3 and TBP gene in A2780 (a., c., e.) cells treated with decitabine  
[25 μM] and RG108 [150 μM] in comparison to control cells. Methylation status of the fragment of promoter region of DIRAS3, STAT3 and TBP gene  
in MCF7 cells (b., d., f.) treated with decitabine [25 μM] and RG108 [150 μM] in comparison to control cells. Methylation status was examined by  
MS-PCR with a methylated primer set (M) and an unmethylated primer set (uM)
Figure 4. The effect of decitabine and RG108 on the cell migration and motility was estimated by the relative distance of wound closure compared 
to control cells. Digital documentation was made after scratching — at time zero (a.) and after 7 days (b.) by inverted microscope (Axiovert, Zeiss)
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MCF7 cells after 7 days compared to time zero and compared 
to control cells were statistically significant.
DISCUSSION
Since genetic alterations are almost impossible to re-
verse, the potential reversibility of epigenetic regulatory 
mechanisms makes them attractive candidates for new tar-
gets in the effort of prevention and treatment of ovarian and 
breast carcinoma. Aberrant DNA CpG island methylation 
within genes’ promoter region represents one possible 
mechanism of gene silencing by cancer [20]. The promoter 
methylation is related to reduction of DIRAS3 expression in 
most ovarian cancer and breast cancer cells [8, 21]. Ovar-
ian and breast cancer cells treated with DNA demethylating 
agents can reactivate both the silenced and the imprinted 
alleles of DIRAS3. DIRAS3 is a cell cycle regulator that inhibits 
cancer cell growth, decreases motility and regulates tumor 
dormancy, all of which may indirectly depend on interaction 
with a transcription factor STAT3 with a potential oncogenic 
role. STAT3 is frequently phosphorylated and activated in the 
majority of breast and ovarian cancers [22, 23]. Barrow et 
al. have observed increasing variation in DNA methylation 
across breast tissue starting from normal through benign to 
cancer tissue ending with even more aberrant methylation 
of DIRAS3 in 36% patients with invasive breast cancer [24]. 
Lu et al. have indicated that loss of DIRAS3 expression in 
ovarian and breast cancer cells might be due to several 
mechanisms eg., maternal imprinting, loss of heterozygosity, 
promoter DNA methylation or decreased histone H3 acety-
lation [25].
Nishimoto et al. have indicated that activated STAT3 has 
been observed in most invasive breast cancers and in many 
breast and ovarian cancer cell lines but not in normal 
cells [13]. High expression of STAT3 has been observed in 
many different ovarian cancer cell lines. Han et al. have 
observed that total STAT3 protein level is expressed, among 
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others, in A2780 and SKOV-3 cells. However, the level of 
phosphorylated STAT3 (pSTAT3) was higher in SKOV-3 cells 
than in the A2780 cells [26]. Nishimoto et al. have also ob-
served that DIRAS3 expression is decreased in breast and 
ovarian cancer cells and properly expressed in normal breast 
and ovarian cells. At the same time they have indicated that 
DIRAS3 associates with STAT3 and plays an important role 
in down-regulating STAT3 activity [13]. Our study confirmed 
that DIRAS3 expression was in fact reduced in ovarian and 
breast cancer cell lines while STAT3 was highly expressed. 
Therefore, decreasing of DIRAS3 expression in ovarian and 
breast cancer cells may provide the mechanism that con-
tributes to high constitutive STAT3 activity [13]. In a study 
comparing the anti-proliferative activity of two demethylat-
ing agents — 5-azacitidine (AZA) and 5-aza-2'-deoxycytidine 
(decitabine, DAC) and two HDAC inhibitors – suberoylanilide 
hydroxamic acid (SAHA) and trichostatin A (TSA) Chen et al. 
report that after 5 days of treatment with DAC the reduction 
in viability at increasing doses could be fitted by hyperbolic 
curves which decreased to asymptotes at approximately 
30% for Hey and 60% for SKOv3 cells. There was no further 
increase in DAC’s anti-proliferative activity at concentrations 
higher than 32 μM in the SKOV-3 cells [27].
In turn, Feng et al. have observed an 8-fold increase of 
DIRAS3 expression in OVCA420 ovarian cancer cells treat-
ed with 5-aza-dC compared to approximately 2- to 4-fold 
increase in Hey, SKOV-3 or OVCA432 cells. Interestingly, 
DIRAS3 expression was not affected in CAOv3 cells when 
treated with demethylating agents [28].
In this study we have observed a statistically signifi-
cant dose dependent effect of decitabine and RG108 on 
DIRAS3 expression in A2780 cells. Interestingly, lower doses 
of decitabine have activated DIRAS3 expression slightly 
more compared to control cells. This is supported by Mund 
et al. and Gil et al. who indicate that decitabine in lower 
doses might induce demethylation even more effectively 
with lower cytotoxicity [29, 30]. RG108 in turn has acti-
vated expression of DIRAS3 proportionally on the dose 
dependent manner. Yet, there was no increase of the DI-
RAS3 expression in MCF7 cells treated with decitabine or 
RG108. We observed no changes in the STAT3 expression 
after decitabine (12.5 μM) and RG108 treatment when com-
pared to A2780 control cells. What is more, compared to 
control cells decitabine at the dose 25 μM has decreased 
the expression of STAT3 in A2780 cells. Similarly, both DN-
MTi treatment showed no influence on the activation of 
STAT3 expression in MCF7 cells.
In this study have also observed a dose dependent in-
fluence of decitabine and RG108 on the in vitro migration 
of A2780 and MCF7 cells. Both DNMTi have significantly 
(p < 0.001) reduced the speed of A2780 and MCF7 cell 
migration in wound healing assay in comparison to un-
treated control cells cultured under standard conditions 
after 7 days. However, A2780 cells treated with decitabine 
[25 μM and 12.5 μM] covered the wound respectively 3.5 and 
2.5 times slower than MCF7 cells while A2780 cells treated 
with RG108 [150 μM and 100 μM] covered the wound 6 and 
3 times slower than MCF7 cells. A2780 and MCF7 control 
cells covered the wound with the same speed. To sum 
up, when the speed of wound healing is considered, hu-
man ovarian carcinoma cells show higher sensitivity to 
DNMTi compared to human breast cancer cells. 
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